| ||STUDY NAME|
|Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials|
|The purpose of this study is to provide anti-HCV drugs to +/- 200 subjects treated in prior
BMS studies with placebo + Peginterferon Alfa-2a and Ribavirin and determine if the addition
of these drugs can result in higher cure rates in patients who previously failed therapy.
Approximately 100 genotype 1b subjects rolling over from BMS study AI447-028 who received
placebo will be treated with active drugs in this study.|